[ad_1]
Adjournment only with respect to proposal 2 (increase in authorized shares) The company and the board of directors to explore alternative options
ROCKVILLE, Md., July 7, 2021 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and computing to fight infectious disease, today announced that the Company has resumed its partially adjourned 2021 annual meeting of shareholders (the “Annual Meetingâ€) on July 7, 2021, only with respect to Proposal 2 set out in its declaration of definitive power of attorney, dated April 26, 2021, relating to the increase in the authorized ordinary shares of the Company. The Company has adjourned the annual meeting on this proposal in order to give its shareholders more time to vote on Proposal 2. The annual meeting will resume on Proposal 2 at 10:00 a.m. Eastern Time on August 5, 2021 and will continue to be held at the offices of the Company located at 9717 Key West Ave, Suite 100, Rockville, MD 20850. * The date of registration to determine shareholders eligible to vote at the annual meeting will remain close of business April 15, 2021.
Oliver Schacht, CEO of OpGen commented: “We are very encouraged by the recent comments and the dialogue with many shareholders and the number of shareholders who have already voted in favor of this important proposal. I cannot stress enough how important this proposal is to the continued success of the Society. As such, our Board unanimously recommends approval of this proposal. While OpGen had a strong cash position of $ 39.4 million at the end of the first quarter of 2021, these additional authorized shares will provide the Company with the flexibility to seek future funding to allow us to continue. to develop, to manage strategically and potentially to repay our long term. term debt and raise additional capital if necessary. However, since we need at least 66.67% of all total OpGen shares outstanding to vote in favor of this proposal for passage, management and our board have decided to simultaneously explore other options to finance the Company’s future development and growth. “
Shareholders at the close of business on April 15, 2021, the registration date of the Annual Meeting, who have not yet voted are invited to vote via the Internet at http://www.pstvote.com/opgen2021 . Shareholders who need help voting or have questions can contact the Company’s proxy firm, Alliance Advisors, LLC, at 800-574-6217 or [email protected].
* As part of our coronavirus (or COVID-19) pandemic precautions, we anticipate the possibility that we may need to change the location of the annual meeting, or the annual meeting may be held only through remote communication. If we take this step, we will announce the decision to do so in advance, and details on how to participate will be available on our website at https://ir.opgen.com/.
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to fight infectious diseases. Together with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we develop and market molecular microbiology solutions that help guide clinicians with faster, actionable information on life-threatening infections to improve patient outcomes and reduce the spread infections caused by multidrug-resistant microorganisms. , or MDROs. OpGen’s product portfolio includes Unyvero®, Acuitas® AMR Gene Panel and Acuitas® Lighthouse, as well as the ARES technology platform including ARESdb®, using NGS technology and AI-powered bioinformatics solutions for prediction of response to antibiotics.
For more information, please visit www.opgen.com.
Forward-looking statements
This press release includes statements regarding the partial adjournment of the OpGen annual meeting. These and other statements regarding OpGen’s Unyvero products, their marketing and launch, their future plans and objectives constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of Securities Exchange Act of 1934 and are intended to qualify for the Safe Harbor of Responsibility established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties which are often difficult to predict, are beyond our control, and which may lead to results that differ significantly from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance to and market our offerings of products and services, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use the proceeds of recent financings, including our November 2020 private placement, the exercise and exchange of warrants registered in February 2021 and March 2021, the realization of the expected benefits of our business combination transaction with Curetis GmbH, the success of our marketing efforts, the impact of COVID -19 on the operations, financial results and marketing efforts of the Company as well as on the capital markets and conditions general economic conditions, the effect on our business of and new regulatory requirements, and other economic and competitive factors. For a discussion of the most important risks and uncertainties associated with OpGen’s business, please see our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We assume no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen: Oliver Schacht President and CEO [email protected]
OpGen press contact: Matthew Bretzius FischTank Marketing and public relations [email protected]
OpGen investor contact: Joe Green Edison Group [email protected]
Copyright 2021 GlobeNewswire, Inc.
[ad_2]
